Raynaud-Syndrom: Neue Erkenntnisse und Entwicklungen

Schlüsselwörter

Raynaud-Phänomen - Raynaud-Syndrom - Kapillarmikroskopie - systemische Sklerose - Bosentan - Phosphodiesterasehemmer - Botulinumtoxin

Keywords

Raynaud‘s phenomenon - Raynaud‘s syndrome - capillary microscopy - systemic sclerosis - bosentan - phosphodiesterase inhibitors - botulinum toxin

• Literatur

• 1 Chikura B, Moore TL, Manning JB et al. Sparing of the thumb in Raynaud`s phenomenon. Rheumatology (Oxford) 2008; 47: 219-221
• 2 Dees C, Akhmetshina A, Zerr P et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208: 961-972
• 3 Heidrich H. Definition und Terminologie des Raynaud-Syndroms. Dtsch Med Wochenschr 2008; 133: 1742-1744
• 4 Heidrich H, Helmis J, Fahrig C et al. Clinical characteristics of primary, secondary, and suspected secondary Raynaud`s syndrome and diagnostic transition in the long-term follow-up. A retrospective study in 900 patients. Vasa 2008; S/73: 3-25
• 5 Hirschl M, Hirschl K, Lenz M et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006; 54: 1974-1981
• 6 Hoerth C, Kundi M, Katzenschlager R et al. Qualitative and quantitative assessment of nailfold capillaries by videocapillaroscopy in healthy volunteers. Vasa 2012; 41: 19-26
• 7 Impens AJ, Phillips K, Schiopu E. PDE-5 inhibitors in scleroderma Raynaud phenomenon and digital ulcers: current status of clinical trials. Int J Rheumatol 2011; 2011: doi:10.1155/2011/392542
• 8 Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Semin Arthritis Rheum 2011; Aug 23. Epub ahead of print
• 9 Koenig M, Joyal F, Fritzler MJ et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902-3912
• 10 Kowal-Bielecka O, Landewé R, Avouac J et al., EUSTAR Co-Authors EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-628
• 11 Sander O, Becker M, Hergott I et al. Interobservervariabilität kapillarmikroskopischer Diagnostik im deutschsprachigen Raum. Z Rheumatol 2011; 70 (Suppl. 01) 1-92
• 12 Sander O, Sunderkötter C, Kötter I et al. Kapillarmikroskopie – Durchführung und Nomenklatur. Z Rheumatol 2010; 69: 253-262
• 13 Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011; 301: H287-H296
• 14 Sebastiani M, Manfredi A, Vukatana G et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis 2012; 71: 67-70
• 15 Sporbeck B, Mathiske-Schmidt K, Jahr S et al. Effect of biofeedback and deep oscillation on Raynaud's phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. Rheumatol Int 2011; Apr 8. Epub ahead of print